For decades, cancer treatment has followed a “one-size-fits-all” approach, leading to many patients experiencing ineffective treatments. Nearly one in three experiences at least one failed treatment, and the limitations of traditional in vitro models have contributed to a staggering 95% failure rate for oncology drugs in clinical trials.

At Pre-Cure, we are transforming cancer treatment with our groundbreaking Tumor-on-a-Chip platform – a miniature, multi-functional biomimetic device that replicates human physiology and the tumor microenvironment using patient-derived tissues. This innovative platform enables precise treatment predictions, paving the way for truly personalized therapy while accelerating drug development.

We are currently conducting clinical trials to validate our platform in ovarian, head & neck, pancreatic, and advanced GI cancers across the full spectrum of treatment modalities. With the potential to impact 5.6 million patients globally each year – including 861,000 in the U.S. and 410,000 in the EU – Pre-Cure is redefining precision oncology.